Unknown

Dataset Information

0

Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson's Disease.


ABSTRACT: Human pluripotent stem cells (PSC) have the potential to revolutionize regenerative medicine. However undifferentiated PSC can form tumors and strict quality control measures and safety studies must be conducted before clinical translation. Here we describe preclinical tumorigenicity and biodistribution safety studies that were required by the US Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) prior to conducting a Phase I clinical trial evaluating the safety and tolerability of human parthenogenetic stem cell derived neural stem cells ISC-hpNSC for treating Parkinson's disease (ClinicalTrials.gov Identifier NCT02452723). To mitigate the risk of having residual PSC in the final ISC-hpNSC population, we conducted sensitive in vitro assays using flow cytometry and qRT-PCR analyses and in vivo assays to determine acute toxicity, tumorigenicity and biodistribution. The results from these safety studies show the lack of residual undifferentiated PSC, negligible tumorigenic potential by ISC-hpNSC and provide additional assurance to their clinical application.

SUBMITTER: Garitaonandia I 

PROVIDER: S-EPMC5055076 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson's Disease.

Garitaonandia Ibon I   Gonzalez Rodolfo R   Christiansen-Weber Trudy T   Abramihina Tatiana T   Poustovoitov Maxim M   Noskov Alexander A   Sherman Glenn G   Semechkin Andrey A   Snyder Evan E   Kern Russell R  

Scientific reports 20160930


Human pluripotent stem cells (PSC) have the potential to revolutionize regenerative medicine. However undifferentiated PSC can form tumors and strict quality control measures and safety studies must be conducted before clinical translation. Here we describe preclinical tumorigenicity and biodistribution safety studies that were required by the US Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) prior to conducting a Phase I clinical trial evaluating the sa  ...[more]

Similar Datasets

| S-EPMC8649581 | biostudies-literature
2009-04-01 | GSE12062 | GEO
| S-EPMC4664819 | biostudies-literature
| S-EPMC5297853 | biostudies-literature
| S-EPMC9837678 | biostudies-literature
| S-EPMC9040239 | biostudies-literature
| S-EPMC10401423 | biostudies-literature
| S-EPMC9957486 | biostudies-literature
| S-EPMC6522948 | biostudies-literature
| S-EPMC7596695 | biostudies-literature